Latest Raloxifene Stories
According to a new report from BCC Research,the global market for women’s health therapeutics is expected to grow to $22.5 billion by 2018, with a five-year compound annual growth rate (CAGR)
- Prasco to market the Authorized Generic of EVISTA® in the United States CINCINNATI, April 1, 2014 /PRNewswire/ -- Prasco
Certain medications can reduce a woman's risk for developing breast cancer.
There is good news for postmenopausal women who are at high risk for developing breast cancer. According to a new study, taking the drug anastrozole for five years reduced the likelihood of developing the disease by 53 percent when compared with women who took a placebo.
ASCO expert panel includes University of New England researcher Nananda Col, M.D., M.P.H. Biddeford, ME (PRWEB) July 16, 2013 The
New research from the Mayo Clinic has identified favorable genetic variations that increase the chances of a positive response to preventive breast cancer therapy with the drugs tamoxifen and raloxifene.
A new study has identified a set of genes that may predict which women are at high risk for getting breast cancer that is sensitive to estrogen. These women maybe also helped by taking drugs to prevent the cancer's development.
When women at high risk of breast cancer viewed a customized web-based decision guide about prevention options, they were more likely to make a choice about prevention and to feel comfortable with their choice.
INDIANAPOLIS, Aug. 9, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data on EVISTAÂ® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion.
- A handkerchief.
- In general, any miraculous portrait of Christ.